Annals of Oncology, volume 33, issue 4, pages 406-415

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

V. Subbiah

R J Kreitman

Z A Wainberg

J Y Cho

J H M Schellens

J.-C. Soria

P.Y. Wen

C. C. ZIELINSKI

M E Cabanillas

A Boran

P Ilankumaran

P. Burgess

T. Romero Salas

B Keam

Show full list: 14 authors

Publication type: Journal Article

Publication date: 2022-04-01

Elsevier

Journal: Annals of Oncology

scimago Q1

SJR: 13.942

CiteScore: 63.9

Impact factor: 56.7

ISSN: 09237534, 15698041

DOI: 10.1016/j.annonc.2021.12.014

Copy DOI

Oncology

Hematology

Found 0

Clear filter

By date By citations

Found 0

Clear filter

By date By citations

Top-30

Journals

	1 2 3 4 5 6 7 8 9
Cancers	Cancers, 9, 5.26% Cancers 9 publications, 5.26%
Frontiers in Endocrinology	Frontiers in Endocrinology, 5, 2.92% Frontiers in Endocrinology 5 publications, 2.92%
npj Precision Oncology	npj Precision Oncology, 4, 2.34% npj Precision Oncology 4 publications, 2.34%
Thyroid	Thyroid, 4, 2.34% Thyroid 4 publications, 2.34%
Endocrine	Endocrine, 4, 2.34% Endocrine 4 publications, 2.34%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 4, 2.34% International Journal of Molecular Sciences 4 publications, 2.34%
Frontiers in Oncology	Frontiers in Oncology, 3, 1.75% Frontiers in Oncology 3 publications, 1.75%
Clinical Thyroidology	Clinical Thyroidology, 3, 1.75% Clinical Thyroidology 3 publications, 1.75%
JAMA Oncology	JAMA Oncology, 3, 1.75% JAMA Oncology 3 publications, 1.75%
Anti-Cancer Drugs	Anti-Cancer Drugs, 2, 1.17% Anti-Cancer Drugs 2 publications, 1.17%
Best Practice and Research in Clinical Endocrinology and Metabolism	Best Practice and Research in Clinical Endocrinology and Metabolism, 2, 1.17% Best Practice and Research in Clinical Endocrinology and Metabolism 2 publications, 1.17%
Annals of Oncology	Annals of Oncology, 2, 1.17% Annals of Oncology 2 publications, 1.17%
The Lancet Oncology	The Lancet Oncology, 2, 1.17% The Lancet Oncology 2 publications, 1.17%
Endocrine Practice	Endocrine Practice, 2, 1.17% Endocrine Practice 2 publications, 1.17%
ESMO Open	ESMO Open, 2, 1.17% ESMO Open 2 publications, 1.17%
American Society of Clinical Oncology Educational Book	American Society of Clinical Oncology Educational Book, 2, 1.17% American Society of Clinical Oncology Educational Book 2 publications, 1.17%
Current Opinion in Endocrine and Metabolic Research	Current Opinion in Endocrine and Metabolic Research, 2, 1.17% Current Opinion in Endocrine and Metabolic Research 2 publications, 1.17%
Frontiers in Immunology	Frontiers in Immunology, 2, 1.17% Frontiers in Immunology 2 publications, 1.17%
Cureus	Cureus, 2, 1.17% Cureus 2 publications, 1.17%
Medicine (United States)	Medicine (United States), 2, 1.17% Medicine (United States) 2 publications, 1.17%
Virchows Archiv	Virchows Archiv, 2, 1.17% Virchows Archiv 2 publications, 1.17%
Nature Reviews Clinical Oncology	Nature Reviews Clinical Oncology, 2, 1.17% Nature Reviews Clinical Oncology 2 publications, 1.17%
JCO Oncology Practice	JCO Oncology Practice, 2, 1.17% JCO Oncology Practice 2 publications, 1.17%
Medicina	Medicina, 2, 1.17% Medicina 2 publications, 1.17%
Cell Death and Disease	Cell Death and Disease, 2, 1.17% Cell Death and Disease 2 publications, 1.17%
European Thyroid Journal	European Thyroid Journal, 2, 1.17% European Thyroid Journal 2 publications, 1.17%
Bulletin du Cancer	Bulletin du Cancer, 2, 1.17% Bulletin du Cancer 2 publications, 1.17%
Nihon Kikan Shokudoka Gakkai Kaiho	Nihon Kikan Shokudoka Gakkai Kaiho, 2, 1.17% Nihon Kikan Shokudoka Gakkai Kaiho 2 publications, 1.17%
JAMA Otolaryngology - Head and Neck Surgery	JAMA Otolaryngology - Head and Neck Surgery, 1, 0.58% JAMA Otolaryngology - Head and Neck Surgery 1 publication, 0.58%
	1 2 3 4 5 6 7 8 9

Publishers

	5 10 15 20 25 30 35 40 45
Springer Nature	Springer Nature, 42, 24.56% Springer Nature 42 publications, 24.56%
Elsevier	Elsevier, 26, 15.2% Elsevier 26 publications, 15.2%
MDPI	MDPI, 22, 12.87% MDPI 22 publications, 12.87%
Frontiers Media S.A.	Frontiers Media S.A., 10, 5.85% Frontiers Media S.A. 10 publications, 5.85%
Mary Ann Liebert	Mary Ann Liebert, 7, 4.09% Mary Ann Liebert 7 publications, 4.09%
Wiley	Wiley, 6, 3.51% Wiley 6 publications, 3.51%
American Medical Association (AMA)	American Medical Association (AMA), 5, 2.92% American Medical Association (AMA) 5 publications, 2.92%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 5, 2.92% American Society of Clinical Oncology (ASCO) 5 publications, 2.92%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 5, 2.92% Ovid Technologies (Wolters Kluwer Health) 5 publications, 2.92%
Taylor & Francis	Taylor & Francis, 4, 2.34% Taylor & Francis 4 publications, 2.34%
The Endocrine Society	The Endocrine Society, 3, 1.75% The Endocrine Society 3 publications, 1.75%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 3, 1.75% Cold Spring Harbor Laboratory 3 publications, 1.75%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 3, 1.75% Georg Thieme Verlag KG 3 publications, 1.75%
American Association of Clinical Endocrinology	American Association of Clinical Endocrinology, 2, 1.17% American Association of Clinical Endocrinology 2 publications, 1.17%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 2, 1.17% American Association for Cancer Research (AACR) 2 publications, 1.17%
S. Karger AG	S. Karger AG, 2, 1.17% S. Karger AG 2 publications, 1.17%
Japan Broncho-esophagological Society	Japan Broncho-esophagological Society, 2, 1.17% Japan Broncho-esophagological Society 2 publications, 1.17%
BMJ	BMJ, 1, 0.58% BMJ 1 publication, 0.58%
Oxford University Press	Oxford University Press, 1, 0.58% Oxford University Press 1 publication, 0.58%
American Society for Clinical Investigation	American Society for Clinical Investigation, 1, 0.58% American Society for Clinical Investigation 1 publication, 0.58%
Endocrinology Research Centre	Endocrinology Research Centre, 1, 0.58% Endocrinology Research Centre 1 publication, 0.58%
IntechOpen	IntechOpen, 1, 0.58% IntechOpen 1 publication, 0.58%
AME Publishing Company	AME Publishing Company, 1, 0.58% AME Publishing Company 1 publication, 0.58%
Bioscientifica	Bioscientifica, 1, 0.58% Bioscientifica 1 publication, 0.58%
Spandidos Publications	Spandidos Publications, 1, 0.58% Spandidos Publications 1 publication, 0.58%
Baishideng Publishing Group	Baishideng Publishing Group, 1, 0.58% Baishideng Publishing Group 1 publication, 0.58%
Impact Journals	Impact Journals, 1, 0.58% Impact Journals 1 publication, 0.58%
SAGE	SAGE, 1, 0.58% SAGE 1 publication, 0.58%
Medknow	Medknow, 1, 0.58% Medknow 1 publication, 0.58%
	5 10 15 20 25 30 35 40 45

We do not take into account publications without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

97 Field Citation Ratio

14 Relative Citation Ratio

Cite this

GOST |

Cite this

GOST Copy

Subbiah V. et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study // Annals of Oncology. 2022. Vol. 33. No. 4. pp. 406-415.

GOST all authors (up to 50) Copy

Subbiah V., Kreitman R. J., Wainberg Z. A., Cho J. Y., Schellens J. H. M., Soria J., Wen P., ZIELINSKI C. C., Cabanillas M. E., Boran A., Ilankumaran P., Burgess P., Romero Salas T., Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study // Annals of Oncology. 2022. Vol. 33. No. 4. pp. 406-415.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/j.annonc.2021.12.014

UR - https://doi.org/10.1016/j.annonc.2021.12.014

TI - Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

T2 - Annals of Oncology

AU - Subbiah, V.

AU - Kreitman, R J

AU - Wainberg, Z A

AU - Cho, J Y

AU - Schellens, J H M

AU - Soria, J.-C.

AU - Wen, P.Y.

AU - ZIELINSKI, C. C.

AU - Cabanillas, M E

AU - Boran, A

AU - Ilankumaran, P

AU - Burgess, P.

AU - Romero Salas, T.

AU - Keam, B

PY - 2022

DA - 2022/04/01

PB - Elsevier

SP - 406-415

IS - 4

VL - 33

SN - 0923-7534

SN - 1569-8041

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2022_Subbiah,

author = {V. Subbiah and R J Kreitman and Z A Wainberg and J Y Cho and J H M Schellens and J.-C. Soria and P.Y. Wen and C. C. ZIELINSKI and M E Cabanillas and A Boran and P Ilankumaran and P. Burgess and T. Romero Salas and B Keam},

title = {Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study},

journal = {Annals of Oncology},

year = {2022},

volume = {33},

publisher = {Elsevier},

month = {apr},

url = {https://doi.org/10.1016/j.annonc.2021.12.014},

number = {4},

pages = {406--415},

doi = {10.1016/j.annonc.2021.12.014}

}

MLA

Cite this

MLA Copy

Subbiah, V., et al. “Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.” Annals of Oncology, vol. 33, no. 4, Apr. 2022, pp. 406-415. https://doi.org/10.1016/j.annonc.2021.12.014.

Found error?

Message

Support chat

Publisher

Elsevier

Journal

Annals of Oncology

scimago Q1

SJR

13.942

CiteScore

63.9

Impact factor

56.7

ISSN

09237534 (Print)

15698041 (Electronic)